Publications

Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Rev Vaccines. 2023 Jan-Dec;22(1):1008-1021. doi: 10.1080/14760584.2023.2273892. Epub 2023 Nov 2. PMID: 37872765.

Read it

Marbaix S, Dauby N, Mould-Quevedo J. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population. Expert Rev Vaccines. 2023 Jan-Dec;22(1):608-619.

Read it

Marbaix S, Peetermans WE, Verhaegen J, Annemans L, R Sato, Mignon A, Atwood M, Wecyker D, Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection, PLOS One, July 6, 2018

Read it

(Referred in the Superior Health Council recommendations on pneumococcal vaccination in adults : )

Have a look

Annemans L, Marbaix S, Nackaerts K, Bartsch P, Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Preventive Medicine Report 2, 2015, 189-195

Read it

Kongnakorn T, Lanitis T, Annemans L, Thijs V, Goethals M, Marbaix S, Wautrecht JC. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin. Clin Drug Investig. 2015 Feb;35(2):109-19. doi: 10.1007/s40261-014-0253-7. PMID: 25511639.

Read it

Kongnakorn T, Lanitis T, Lieven A, Thijs V, Marbaix S. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Clin Drug Investig. 2014 Oct;34(10):709-21. doi: 10.1007/s40261-014-0224-z. Erratum in: Clin Drug Investig. 2014 Oct;34(10):753. Annemans, Lievens [corrected to Lieven, Annemans]. PMID: 25164005.

Read it

Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective. Acta Clin Belg. 2012 Nov-Dec;67(6):416-22. doi: 10.2143/ACB.67.6.2062706. PMID: 23340147.

Read it

Annemans L, Marbaix S, Webb K, Van Gaal L, Scheen A. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population. Clin Drug Investig. 2010;30(2):133-42. doi: 10.2165/11531910-000000000-00000. PMID: 20067331.

Read it

Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg. 2008 May-Jun;63(3):170-8. doi: 10.1179/acb.2008.027. PMID: 18714847.

Read it

Liew D, Webb K, Marbaix S, Annemans L. Changes to the statin prescribing policy in Belgium: potential impact in clinical and economic terms, Am J cardiovasc drugs 2012 : 12 (4) : 1-8

Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix, Cost effectiveness of varenicline in Belgium, compared with bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation. A BENESCO Markov Cost-Effectiveness Analysis. Clin Drug Investig 2009; 29 (10) : 655-665

Selleslag D, Vogelaers D, Marbaix S, Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium, Acta Clinica Belgica, 2009;64-5 (393-398)

Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork A-Ch., Aubin H-J, Cost-effectiveness of varenicline compared with nicotine patch for smoking cessation-results from 4 European countries, European Journal of Public Health 2009, 1-5

Van Campenhout H, Marbaix S., Derde M-P and Annemans L, Voriconazole Treatment of Invasive Aspergillosis : Real-World versus Health-Economic Model Results, Clin Drug Invest 28 (8) : 509-521, 2008

Annemans L, Beutels P, Bloom DE, De Backer W, Ethgen O, Luyten J, Van Wilder P, Willem L, Simoens S. Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. Value Health. 2021 Jan;24(1):105-111. doi: 10.1016/j.jval.2020.09.005. Epub 2020 Dec 11. PMID: 33431141.

Read it

Cleemput I, Neyt M, Van de Sande S, Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre(KCE). 2012. KCE Report 183C. D/2012/10.273/54

Read it

Selleslag D, Vogelaers D., Marbaix S., Economic evaluation versus caspofungin for the treatment of invasive aspergillosis, poster presented at the BSH congress, January 2009

Marbaix S, Vandenberghe H, Van Gaal, Cost-effectiveness of atorvastatin in Type 2 diabetes patients : a pharmaco-economic analysis of the Collaborative Atorvastatin Diabetes Study (CARDS) in the Belgian population, poster presented at ISPOR European congress, November 2008

Van Nooten F, Dewilde S, Marbaix S, Cost-effectiveness of sunitinib as 2nd line treatment in Patients with metastatic renal cell carcinoma (mRCC) in Belgium, poster presented at ISPOR European congress, November 2007

Marbaix S, Marciniak A, De Mees V., Aoun M, Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium, poster presented at ISPOR European congress, November 2003